Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Long-Term Deferred Tax (2020 - 2024)

Historic Long-Term Deferred Tax for Inmune Bio (INMB) over the last 5 years, with Q4 2024 value amounting to $25.7 million.

  • Inmune Bio's Long-Term Deferred Tax rose 3112.24% to $25.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $25.7 million, marking a year-over-year increase of 3112.24%. This contributed to the annual value of $25.7 million for FY2024, which is 3112.24% up from last year.
  • According to the latest figures from Q4 2024, Inmune Bio's Long-Term Deferred Tax is $25.7 million, which was up 3112.24% from $545000.0 recorded in Q3 2024.
  • Over the past 5 years, Inmune Bio's Long-Term Deferred Tax peaked at $25.7 million during Q4 2024, and registered a low of $545000.0 during Q3 2024.
  • Over the past 5 years, Inmune Bio's median Long-Term Deferred Tax value was $6.8 million (recorded in 2021), while the average stood at $10.1 million.
  • Per our database at Business Quant, Inmune Bio's Long-Term Deferred Tax surged by 10222.32% in 2022 and then soared by 3112.24% in 2024.
  • Inmune Bio's Long-Term Deferred Tax (Quarter) stood at $3.5 million in 2020, then surged by 91.49% to $6.8 million in 2021, then surged by 102.22% to $13.7 million in 2022, then soared by 42.7% to $19.6 million in 2023, then soared by 31.12% to $25.7 million in 2024.
  • Its Long-Term Deferred Tax was $25.7 million in Q4 2024, compared to $545000.0 in Q3 2024 and $590000.0 in Q2 2024.